Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company headquartered in Boston, Massachusetts. Founded in 2014 by Thomas J. Schuetz, the company is dedicated to developing proprietary antibody-based therapeutics that broadly drug the immune system to treat various cancers. The company's proprietary antibody discovery engine enables an unbiased approach to ...Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company headquartered in Boston, Massachusetts. Founded in 2014 by Thomas J. Schuetz, the company is dedicated to developing proprietary antibody-based therapeutics that broadly drug the immune system to treat various cancers. The company's proprietary antibody discovery engine enables an unbiased approach to drug development, allowing it to target multiple immune checkpoints and signaling pathways simultaneously. Among its leading clinical-stage programs are CTX-009, a bispecific antibody designed to inhibit Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling, both crucial for tumor vascularization; CTX-471, an IgG4 monoclonal antibody that activates CD137; and CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1. Financially, the company reports a market capitalization of approximately $387 million, with an active trading presence on NASDAQ (ticker: CMPX). As of the latest data, it employs 39 full-time staff, indicating a lean operational structure typical of clinical-stage biotech firms. The company's financial metrics show no revenue generation, as expected for pre-commercialization entities, with operating losses reflecting significant investment in R&D. It maintains a strong balance sheet with a current ratio of 11.2 and cash per share of $0.96, providing runway for ongoing trials. Key leadership includes co-founder and CEO Thomas J. Schuetz, who brings over 20 years of oncology and venture investing experience. The company actively seeks strategic partnerships for pipeline advancement and discovery collaborations, while also offering an attractive compensation package to talent. With a focus on innovative antibody engineering, Compass Therapeutics aims to transform cancer treatment and improve patient outcomes.
